Industry: Health Care Distributors
Company size: XX-Large
Is Sinopharm a good stock investment?
Read the winner biography on Yulin Wei:
Based on the annual Obermatt CEO of the Year analysis, Yulin Wei (Sinopharm) earned the following Obermatt pins for the management performance.
Performance Overview Yulin Wei
Based on the analysis from the Obermatt CEO of the Year ranking, Yulin Wei delivered the following performance over four participations in Obermatt CEO competitions (including possible tenures at other companies):
CEO performance is displayed relative to that of other CEOs that competed in the same categories for the same number of competitions. A ranking of 85 in Combined Performance indicates that Yulin Wei was better than 85% of all other CEOs that were analyzed as part of the China 100 Ranking – China for 4 participations in Obermatt CEO competitions. Yulin Wei’s average ranking can be found in the Multi-Year Rankings for China 100 Ranking - China.